Daxor announces a new research letter in the Journal of the American College of Cardiology – Heart Failure validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. The study, titled “Discordant Pressure-Volume Trends During CardioMEMS Monitoring,” evaluated the correlation of pressure-volume profiles over two time periods in a series of heart failure patients who underwent CardioMEMS implantation to measure pressure, and direct measurement of total blood volume using Daxor’s blood volume analysis diagnostic. Veraprapas Kittipibul M.D., lead investigator of the study reported statistically insignificant correlation between the two diagnostics and concluded, “Less than half of patients had concordant pressure-volume changes during CardioMEMS monitoring. Universal volume-directed interventions in HF patients with high pressures might not be appropriate and should be discouraged.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DXR:
- JACC-HF Study Compares Daxor’s BVA-100® Volume Metric to CardioMEMS® Pressure Metric in Heart Failure Patients
- Daxor announces further acquisitions, increased utilization of BVA-100
- Daxor awarded $1.1M order from U.S. Defense Health Agency
- Daxor Corporation Awarded $1.1 Million Contract from the United States Defense Health Agency for Added Capabilities to its Point-of-Care Blood Volume Analyzer
- Daxor Corporation Announces Partial Exercise of Over-Allotment Option in Secondary Offering